C WorldWide Group Holding A S reduced its stake in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 14.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,100 shares of the biotechnology company’s stock after selling 358 shares during the period. C WorldWide Group Holding A S’s holdings in bluebird bio were worth $221,000 at the end of the most recent quarter.
Other institutional investors also recently made changes to their positions in the company. Bank of Montreal Can boosted its position in shares of bluebird bio by 118.9% in the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after buying an additional 911 shares during the last quarter. Affinity Investment Advisors LLC bought a new position in shares of bluebird bio during the second quarter valued at about $246,000. First Mercantile Trust Co. boosted its position in shares of bluebird bio by 14.4% in the first quarter. First Mercantile Trust Co. now owns 2,897 shares of the biotechnology company’s stock valued at $263,000 after buying an additional 365 shares during the last quarter. Berkeley Capital Partners LLC bought a new position in shares of bluebird bio during the first quarter valued at about $282,000. Finally, Teacher Retirement System of Texas bought a new position in shares of bluebird bio during the first quarter valued at about $291,000.
bluebird bio, Inc. (NASDAQ:BLUE) opened at 93.95 on Friday. The firm’s market cap is $4.28 billion. The firm’s 50-day moving average price is $98.52 and its 200 day moving average price is $90.12. bluebird bio, Inc. has a 52-week low of $37.05 and a 52-week high of $123.75.
bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) EPS for the quarter, missing analysts’ consensus estimates of ($1.66) by $0.07. The business had revenue of $16.70 million during the quarter, compared to analysts’ expectations of $6.29 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The company’s revenue for the quarter was up 977.4% on a year-over-year basis. During the same period in the prior year, the company posted ($1.59) EPS. On average, equities research analysts forecast that bluebird bio, Inc. will post ($6.78) EPS for the current year.
TRADEMARK VIOLATION WARNING: “C WorldWide Group Holding A S Sells 358 Shares of bluebird bio, Inc. (NASDAQ:BLUE)” was posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/08/12/c-worldwide-group-holding-a-s-sells-358-shares-of-bluebird-bio-inc-nasdaqblue.html.
Several brokerages have recently issued reports on BLUE. BTIG Research reiterated a “buy” rating and issued a $112.00 price objective on shares of bluebird bio in a research note on Thursday, June 1st. Zacks Investment Research cut bluebird bio from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. BidaskClub cut bluebird bio from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Jefferies Group LLC reiterated a “buy” rating and issued a $88.00 price objective on shares of bluebird bio in a research note on Friday. Finally, Maxim Group upgraded bluebird bio from a “hold” rating to a “buy” rating and set a $100.00 price objective for the company in a research note on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $100.66.
In other bluebird bio news, Director Daniel Lynch sold 2,000 shares of the stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $80.00, for a total transaction of $160,000.00. Following the transaction, the director now owns 3,400 shares of the company’s stock, valued at approximately $272,000. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Eric Sullivan sold 6,787 shares of the stock in a transaction that occurred on Thursday, June 29th. The stock was sold at an average price of $108.96, for a total value of $739,511.52. Following the transaction, the insider now directly owns 8,466 shares in the company, valued at approximately $922,455.36. The disclosure for this sale can be found here. Insiders sold 77,856 shares of company stock valued at $8,093,145 in the last three months. 3.90% of the stock is currently owned by company insiders.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
What are top analysts saying about bluebird bio Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for bluebird bio Inc. and related companies.